Zolgensma Market Report 2026

Zolgensma Market Overview

• The Zolgensma market growth in the historic period has been driven by improvements in gene therapy delivery platforms, clinical success in treating SMA type 1 • Market expansion is supported by increasing investment in gene therapy pipelines, expansion of newborn screening programs • Growth Driver: Increasing Incidence of Spinal Muscular Atrophy Drives Demand for Gene Therapy Solutions • North America was the largest region in 2025.

What Is Covered Under Zolgensma Market?

Zolgensma refers to a gene therapy developed to treat spinal muscular atrophy (SMA), a rare genetic disorder that leads to muscle weakness and motor function loss. It is used for replacing the defective or missing SMN1 gene in children under the age of two, helping to restore motor function and improve survival outcomes. The main indications on the solgensma include spinal muscular atrophy (SMA) type 1, spinal muscular atrophy (SMA) type 2, spinal muscular atrophy (SMA) type 3, and pre-symptomatic spinal muscular atrophy (SMA). Spinal muscular atrophy (SMA) type 1 refers to the most severe form of SMA, a genetic disorder characterized by the rapid degeneration of motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy. The various age groups include pediatric (infants and children) and adults and are distributed through several channels such as hospitals, specialty clinics, and pharmacies.

What Is The Zolgensma Market Growth Forecast?

The growth in the forecast period can be attributed to increasing investment in gene therapy pipelines, expansion of newborn screening programs, rising demand for curative rare disease treatments, advancements in viral vector manufacturing, growing focus on long-term health economics benefits. Major trends in the forecast period include increasing adoption of one-time gene therapies, rising focus on early genetic intervention, growing use of viral vector technologies, expansion of curative treatment approaches, enhanced emphasis on long-term survival outcomes.

Global Zolgensma Market Segmentation

1) By Indication: Spinal Muscular Atrophy (SMA) Type 1, Spinal Muscular Atrophy (SMA) Type 2, Spinal Muscular Atrophy (SMA) Type 3, Pre-symptomatic Spinal Muscular Atrophy (SMA) 2) By Age Group: Pediatric (Infants And Children), Adults 3) By Distribution Channel: Hospitals, Specialty Clinics, Pharmacies

What Are The Drivers Of The Zolgensma Market?

Increasing incidence of spinal muscular atrophy is expected to propel the growth of the zolgensma market going forward. Spinal muscular atrophy (SMA) is a genetic disorder characterized by the degeneration of motor neurons in the spinal cord, leading to progressive muscle weakness and atrophy, primarily affecting infants and young children, and potentially resulting in significant physical disabilities and life-threatening complications. The increasing incidence of spinal muscular atrophy (SMA) can be attributed to improved genetic testing and newborn screening programs, which facilitate earlier and more accurate diagnoses, leading to greater identification of cases that may have previously gone unrecognized. Zolgensma works by delivering a functional copy of the SMN1 gene to patients with spinal muscular atrophy (SMA), thereby addressing the underlying genetic cause of the disease and helping to restore the production of the survival motor neuron (SMN) protein, which is critical for motor function and muscle strength, ultimately improving motor skills and survival in affected infants and young children. For instance, in August 2025, according to the Nice organization, a UK-based provides health guidance, Spinal muscular atrophy (SMA) is estimated to occur in roughly 1 out of every 14,000 births worldwide, and in the UK alone around 47 babies were born with SMA in 2023. Therefore, the increasing incidence of spinal muscular atrophy is driving the growth of the zolgensma industry. Rising prevalence of rare diseases is expected to propel the growth of the zolgensma market going forward. A rare disease is a medical condition that affects a small percentage of the population, often characterized by unique symptoms and challenges in diagnosis and treatment. The rising incidence of rare diseases can be attributed to improved diagnostic tools and greater awareness, which facilitate earlier detection and identification of conditions that may have previously gone unrecognized. Zolgensma treats patients with rare diseases like spinal muscular atrophy by delivering a functional copy of the defective SMN1 gene, enabling the production of the SMN protein critical for motor neuron survival and muscle function. For instance, in September 2024, according to the European Union, a Netherlands-based international organization, there are over 6,000 distinct rare diseases that collectively affect up to 36 million people across the European Union. Therefore, the rising prevalence of rare diseases is driving the growth of the zolgensma industry. The rising healthcare expenditure is expected to propel the growth of the zolgensma market going forward. Healthcare expenditure refers to the total financial resources spent by individuals, organizations, or governments on preventing, treating, and managing health conditions. Healthcare expenditure is increasing due to advancements in medical technology, as new diagnostic tools, treatments, and innovative therapies often come at higher costs, leading to greater overall spending in healthcare. Healthcare expenditure drives access to advanced therapies, supporting the adoption of high-cost treatments like Zolgensma by enabling broader patient coverage and reimbursement. For instance, in December 2024, according to the Centers for Medicare & Medicaid Services, a US-based agency responsible for administering the Medicare and Medicaid programs, in 2023, U.S. health care expenditures increased by 7.5%, climbing to $4.9 trillion, or roughly $14,570 for each individual. Therefore, the rising healthcare expenditure is driving the growth of the zolgensma industry.

Key Players In The Global Zolgensma Market

Major companies operating in the zolgensma market are Novartis AG

Regional Insights

North America was the largest region in the zolgensma market in 2025. The regions covered in this market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

What Defines the Zolgensma Market?

The zolgensma market consists of infusion sets, syringes, and other medical supplies for intravenous administration. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Zolgensma Market Report 2026?

The zolgensma market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the zolgensma industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.